**HIGHLIGHTS**

2387  Selected Articles from This Issue

**COMMENTARY**

2389  Translating Cancer Risk Prediction Models into Personalized Cancer Risk Assessment Tools: Stumbling Blocks and Strategies for Success
Erika A. Waters, Jennifer M. Taber, Amy McQueen, Ashley J. Houston, Jamie L. Studts, and Laura D. Scherer

2454  Prostate Cancer Biomarker Development: National Cancer Institute’s Early Detection Research Network Prostate Cancer Collaborative Group Review
Michael A. Liss, Robin J. Leach, Martin G. Sanda, and Oliver J. Semmes

2463  The Evolution of Our Understanding of the Biology of Cancer Is the Key to Avoiding Overdiagnosis and Overtreatment
Kelly Hewitt, Jennifer Son, Alexa Glencer, Alexander D. Borowsky, Matthew R. Cooperberg, and Laura J. Esserman

**CEBP FOCUS**

2396  The National Cancer Institute Early Detection Research Network: Two Decades of Progress
Robert C. Bast Jr and Sudhir Srivastava

2401  The Early Detection Research Network: A National Infrastructure to Support the Discovery, Development, and Validation of Cancer Biomarkers
Sudhir Srivastava and Paul D. Wagner

2411  Biomarkers for Lung Cancer Screening and Detection
Edwin J. Ostrin, David Sidransky, Avrum Spira, and Samir M. Hanash

2416  Noninvasive Diagnostics for Early Detection of Lung Cancer: Challenges and Potential with a Focus on Changes in DNA Methylation
Maria Farooq and James G. Herman

2423  Lung Cancer and Immunity Markers
Raymond J. Lim, Bin Liu, Kostyantyn Krysan, and Steven M. Dubinett

2431  Biomarkers for Early Detection of Colorectal Cancer: The Early Detection Research Network, a Framework for Clinical Translation
Robert S. Bresalier, William M. Grady, Sanford D. Markowitz, Hans Jørgen Nielsen, Surinder K. Batra, and Paul D. Lampe

2441  Tumor DNA as a Cancer Biomarker through the Lens of Colorectal Neoplasia
Joshua D. Cohen, Brenda Diergaarde, Nickolas Papadopoulos, Kenneth W. Kinzler, and Robert E. Schoen

2475  Autoantibodies in Early Detection of Breast Cancer
Femina Rauf, Karen S. Anderson, and Joshua LaBaer

2486  Barrett’s Esophagus and Esophageal Adenocarcinoma Biomarkers
William M. Grady, Ming Yu, Sanford D. Markowitz, and Amitabh Chak

2495  Biomarkers for the Early Detection of Hepatocellular Carcinoma
Neehar D. Parikh, Anand S. Mehta, Amit G. Singal, Timothy Block, Jorge A. Marrero, and Anna S. Lok

2504  Biomarkers and Strategies for Early Detection of Ovarian Cancer
Robert C. Bast Jr, Zhen Lu, Chae Young Han, Karen H. Lu, Karen S. Anderson, Charles W. Drescher, and Steven J. Skates

2513  Biomarkers and Strategy to Detect Preinvasive and Early Pancreatic Cancer: State of the Field and the Impact of the EDRN
Ying Liu, Sukhwinder Kaur, Ying Huang, Johannes F. Fahrmann, Jo Ann Rinaudo, Samir M. Hanash, Surinder K. Batra, Aatur D. Singh, Randall E. Brand, Anirban Maitra, and Brian B. Haab
TABLE OF CONTENTS

2693 Glucosamine and Chondroitin Supplements and Risk of Colorectal Adenoma and Serrated Polyp
Dong Hoon Lee, Chao Cao, Xiaoyu Zong, Xuehong Zhang, Kelli O’Connell, Mingyang Song, Kun Wu, Mengmeng Du, Yin Cao, Edward L. Giovannucci, and Elizabeth D. Kantor

2702 Evaluation of Circulating Tumor DNA for Methylated BCAI and IKZF1 to Detect Recurrence of Stage II/Stage III Colorectal Cancer (CRC)
Benjamin L. Musher, Joshua E. Melson, Gianni Amato, David Chan, Marisa Hill, Iftekhar Khan, Joel Saltzman, Jennifer Silinsky, Snigdha Gaur, Melissa K. Tuck, Lawrence C. LaPointe, and Graeme P. Young

2710 Estimating Population-Based Recurrence Rates of Colorectal Cancer over Time in the United States
Natalia Kunst, Fernando Alarid-Escudero, Eline Aas, Veerle M.H. Coupée, Deborah Schrag, and Karen M. Kuntz

2719 Genetic Variants in the Regulatory T cell–Related Pathway and Colorectal Cancer Prognosis

2729 Auto-antibodies to p53 and the Subsequent Development of Colorectal Cancer in a U.S. Prospective Cohort Consortium

NULL RESULTS IN BRIEF

2735 Mendelian Randomization Analysis of n-6 Polyunsaturated Fatty Acid Levels and Pancreatic Cancer Risk

ASPO REPORT

2740 The Role of Dissemination and Implementation Research in Global Tobacco Control: A Report from the American Society of Preventive Oncology
Ramzi G. Salloum, Mark Parascandola, Jennifer H. LeLaurin, and Donna Shelley

AC AC icon indicates AuthorChoice
For more information please visit www.aacrjournals.org
ABOUT THE COVER

The cover image is adapted from Figure 3 in the article, "Prostate Cancer Biomarker Development: National Cancer Institute’s Early Detection Research Network Prostate Cancer Collaborative Group Review," by Liss and colleagues. The figure shows an MRI-Ultrasound Fusion-guided technique for targeted prostate biopsy. Prostate cancer remains the most common non-skin cancer and second leading cause of death among men in the United States. Although progress has been made in diagnosis and risk assessment, many clinical questions remain regarding early identification of prostate cancer and management. The early detection of aggressive disease continues to provide high curative rates if diagnosed in a localized state. Unfortunately, prostate cancer displays significant heterogeneity within the prostate organ and between individual patients, making detection and treatment strategies complex. Although prostate cancer is common among men, the majority will not die from prostate cancer, introducing the issue of overtreatment as a major concern in clinical management of the disease. The focus of the future is to identify those at highest risk for aggressive prostate cancer and to develop prevention and screening strategies, as well as discerning the difference in malignant potential of diagnosed tumors. The Prostate Cancer Research Group of the National Cancer Institute’s Early Detection Research Network (EDRN) has contributed to the progress in addressing these concerns. The strong focus on biomarker application optimizes the development of biomarkers with clinical utility as well as the early adoption of disruptive technologies, such as MRI imaging, into biomarker development workflows. Likewise, efforts to validate findings from laboratories outside of the EDRN, such as polygenic risk scores and capture of in-depth data from clinical cohorts provide unique resources to the biomarker community. For more information, see the article beginning on page 2454.